Drug Profile

BWV 302

Alternative Names: BWV-302; Malaria/norovirus vaccine - Onconetix; Norovirus-malaria vaccine; Norovirus/malaria vaccine - Onconetix

Latest Information Update: 20 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Blue Water Vaccines
Developer Onconetix
Class Malaria vaccines; Protein vaccines; Viral vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Malaria; Norovirus infections

Most Recent Events

18 Dec 2023 Proteomedix has merged with Blue Water Biotech to form Onconetix
24 Apr 2023 Blue Water Vaccines is now called Blue Water Biotech
24 Mar 2022 Blue Water Vaccines plans to initiate IND-enabling studies for BWV 302 in second half of 2022 (Blue Water Vaccines pipeline, March 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com